Federal regulators have broadened the approved use of a radioactive prostate-cancer therapy so that many more men can receive it, and receive it earlier in the course of their disease. The move roughly doubles the number of patients eligible for a treatment that delivers radiation directly to tumor cells.
The therapy belongs to a class called radioligand treatments, which pair a radioactive particle with a molecule that homes in on cancer. By seeking out a protein found on prostate tumor cells, the drug concentrates its radiation where it is needed while largely sparing healthy tissue.
How Pluvicto finds and irradiates tumors
The drug, Pluvicto, combines a radioactive isotope of lutetium with a molecule that binds to prostate-specific membrane antigen, a protein displayed on the surface of most prostate cancer cells. Once attached, the therapy releases radiation at close range, damaging the DNA of the tumor cell and killing it. Because the targeting molecule seeks out cells carrying that specific antigen, the radiation is delivered in a comparatively focused way. The Food and Drug Administration described the broadened use in its official notice.
What changed with the expanded label
Previously, Pluvicto was reserved for men whose cancer had already become resistant to hormonal treatment and, in practice, for those who had progressed after chemotherapy. The expanded approval allows the drug to be used earlier, in men with PSMA-positive metastatic prostate cancer that is still responsive to hormone-directed treatment, when combined with an androgen receptor pathway inhibitor and androgen deprivation therapy. Moving the therapy up in the treatment sequence means patients can access it before their disease reaches the most treatment-resistant stage, as summarized in coverage compiled by Drugs.com.
The trial that supported the decision
The expansion was backed by a large phase 3 study in which adding Pluvicto to standard care reduced the risk of disease progression or death by 28 percent compared with standard care alone. That reduction, measured against an established treatment regimen, gave regulators evidence that bringing the radioligand therapy forward could delay the cancer’s advance in a broader group of men. Demonstrating benefit earlier in the disease is a higher bar than showing it in heavily pretreated patients, because the comparison is against therapies that already work reasonably well at that stage.
The trial’s design speaks to how oncologists think about sequencing treatments. In advanced prostate cancer, the order in which therapies are given can influence how long each remains useful, and moving an effective option forward risks leaving fewer choices for later if the cancer progresses. Regulators therefore look for clear evidence that the earlier use genuinely delays the disease rather than simply shifting the timing of treatment. A statistically meaningful reduction in the risk of progression or death, measured on top of the current standard, is the kind of result that justifies a shift in practice.
Why treating earlier can matter
Prostate cancer that has spread beyond the gland is generally managed first with treatments that suppress the male hormones fueling the tumor. Over time, many cancers escape that control and become castration-resistant, at which point they are harder to treat. By allowing Pluvicto to be used while the cancer is still hormone-sensitive, the expanded approval aims to strike before that resistance develops. The hope is that layering targeted radiation onto hormonal therapy from the outset keeps the disease in check for longer.
The safety considerations with radioligand therapy
Delivering radiation through the bloodstream carries its own set of precautions. The isotope circulates before concentrating on tumor cells, and organs that naturally take up the targeting molecule, such as the salivary glands and kidneys, can be affected. Patients receiving the therapy follow radiation-safety guidance for a period after each dose, and clinicians monitor blood counts and organ function. Expanding use to more men, and to an earlier setting, means these safety considerations will apply to a larger population, making careful patient selection important.
What the expansion means for prostate cancer care
Radioligand therapy has emerged as one of the more distinctive advances in prostate cancer, offering a way to attack tumors that differs from surgery, external radiation, hormonal drugs, and chemotherapy. By nearly doubling the pool of eligible patients and permitting earlier treatment, the broadened approval positions the approach as a more central part of care rather than a last resort. For men facing metastatic prostate cancer, it adds an option that can now be considered sooner, when it may have the greatest chance to slow the disease.
The approach also depends on a companion diagnostic step that shapes who can receive the drug. Before treatment, patients typically undergo a specialized imaging scan that detects the target protein on their tumors, confirming that the cancer will actually take up the therapy. That pairing of a diagnostic test with a treatment is a hallmark of the field sometimes called theranostics, in which the same molecular target is used both to locate disease and to attack it. Expanding the eligible population means more men will move through that imaging pathway on the way to deciding whether the radioligand therapy is right for them.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
